A cyst is a closed sac-like structure consisting of an epithelial or membrane lining that encloses fluid, air, pus, semisolid material, or other substances, and it can form within any tissue of the body, including the skin, organs, bones, and soft tissues.[1][2] Most cysts are benign and noncancerous, often developing asymptomatically and resolving without intervention, though they may occasionally become inflamed, infected, or cause complications requiring medical attention.[2]Cysts arise from various causes, including blockage of glandular ducts (such as in sebaceous or epidermal cysts), injury or trauma to tissues, infections, foreign bodies embedded in the skin, or parasitic infestations like roundworms or tapeworms affecting organs such as the liver, brain, lungs, or eyes.[1][3] They can also result from developmental abnormalities or hormonal influences, as seen in functional ovarian cysts that form during the menstrual cycle.[4] While many cysts produce no symptoms, larger or infected ones may cause localized pain, swelling, tenderness, redness, or changes in skin appearance, and in internal locations, they might lead to pressure on surrounding structures or organ dysfunction.[3][1]Among the most common types are epidermal inclusion cysts (also known as sebaceous or epidermoid cysts), which are the predominant cutaneous cysts and typically present as firm, slow-growing nodules under the skin filled with keratin; these occur most frequently on the face, neck, trunk, genitals, chest, or back.[5][6] Other prevalent varieties include ovarian cysts, which are fluid-filled sacs on or within the ovaries affecting many women during reproductive years; kidney cysts, often simple and harmless fluid pouches on the kidney surface that increase with age; ganglion cysts, jelly-like lumps near joints or tendons, especially in the wrist; and pilar (trichilemmal) cysts, which are hereditary and common on the scalp, affecting 5-10% of the population.[4][7][8][9] Less common but notable types encompass dermoid cysts, which may contain tissues like hair or bone; arachnoid cysts in the brain or spinal cord, often congenital; and pancreatic or liver cysts, typically incidental findings on imaging.[10][11][12]Diagnosis of cysts usually involves physical examination, imaging such as ultrasound or CT scans to assess size, contents, and characteristics (e.g., uniform fluid-filled cysts are nearly always benign), and sometimes biopsy to rule out malignancy, particularly if solid components are present.[2] Treatment is often unnecessary for asymptomatic cysts but may include drainage, surgical excision, or antibiotics for infected cases, with the approach tailored to the cyst's location, size, and symptoms.[3][1] Although rare, certain cysts can be associated with underlying conditions like polycystic ovary syndrome or may rarely harbor cancer, underscoring the importance of monitoring and evaluation.[13][2]
Overview and Characteristics
Definition and Formation
A cyst is defined as a pathological, fluid-filled sac within the body, bounded by a distinct membrane lined by epithelium, and containing liquid, semi-solid, or gaseous material. This structure distinguishes cysts from other fluid collections, such as effusions or hematomas, due to the presence of a true wall that separates the contents from surrounding tissues.[15] Cysts can arise in various organs and tissues, representing a common benign pathological entity across medical practice.[2]Cysts form through several key mechanisms, including epithelial budding from developmental remnants, obstruction of ducts or glands leading to retention of secretions, and accumulation of fluid following trauma or inflammation.[16] Epithelial budding involves proliferation of epithelial cells that invaginate to create a closed sac, often seen in congenital or developmental cysts. Duct blockage, such as in sebaceous or salivary cysts, results in buildup of endogenous material behind the obstruction.[3]Trauma or inflammatory processes can trigger serous or hemorrhagic fluid collection within a fibrous capsule.[17] Cysts are broadly described as simple or complex: simple cysts are unilocular with thin, smooth walls and anechoic, clear fluid, while complex cysts feature septations, nodular walls, or internal debris, potentially indicating higher risk for complications. These structural differences aid in initial assessment, though full classification relies on etiological factors.[18]Cysts represent common benign lesions in the general population, with prevalence varying by type, location, and age. Autopsy and imaging studies indicate that simple cysts occur frequently; for instance, simple renal cysts are present in approximately 25% of individuals aged 40 years or older and up to 50% of those aged 50 years or older.[19] Similar patterns hold for other sites, such as hepatic simple cysts in 2-18% of adults depending on detection method, underscoring their ubiquity as non-neoplastic entities.[20]The basic pathophysiology of cyst expansion involves fluid secretion by the lining epithelium and osmotic effects from accumulated contents like desquamated epithelial debris or proteins, creating hydrostatic pressure gradients that promote gradual enlargement, often without symptoms until significant size is reached. In many cases, the lining epithelium remains cuboidal or flattened, contributing minimally to proliferation but facilitating sustained secretion.[16]
Histological and Pathological Features
Cysts exhibit distinct histological features that differentiate true cysts from pseudocysts based on their lining and wall composition. True cysts are characterized by an epithelial lining, which can vary in type depending on the cyst's origin; common linings include stratified squamous epithelium, as seen in epidermoid cysts, simple cuboidal or columnar epithelium in glandular-derived cysts, and occasionally pseudostratified or ciliated variants. The cyst wall in true cysts is typically thin, consisting of a layer of connective tissue supporting the epithelium, though thickness can increase with chronicity or inflammation. In contrast, pseudocysts lack an epithelial lining and are enclosed by a fibrous capsule of granulation and scar tissue, often forming as a reactive process without true cellular demarcation.[15]Pathological variations in cysts range from simple to complex forms, influencing their clinical behavior. Simple cysts are unilocular, containing clear serous fluid, with a smooth thin wall and no internal septations or solid components, reflecting a benign, static process. Complex cysts, however, are multilocular with internal septations, thicker irregular walls, and potential solid mural nodules or debris, which may indicate more dynamic pathology such as hemorrhage or degeneration. These features heighten risks of complications, including infection from bacterial ingress into the fluid, hemorrhage leading to rapid expansion, and rare malignant transformation in epithelial-lined cysts with atypical cellular changes.[18]Histology-specific complications further define cyst pathology. Calcification may occur within the wall or contents, particularly in longstanding or parasitic cysts, resulting in dystrophic deposits that alter structural integrity. Keratinization is prominent in epidermoid cysts, where the stratified squamous lining produces laminated keratin flakes, potentially leading to rupture and inflammation. Larger cysts, often exceeding 5 cm in diameter, can exert pressure effects on adjacent tissues, causing compressive symptoms despite initially asymptomatic growth.[21][22][23]
Terminology and Classification
Etymology and Common Terms
The term "cyst" originates from the Greek word kystis, meaning "bladder," "pouch," or "sac," referring to a hollow, fluid-containing structure. This etymological root entered medical terminology through Late Latin cystis and was first documented in English in the early 18th century, around 1736, to describe pathological sacs or vesicles in the body.[24] Anatomists such as Giovanni Battista Morgagni described various cystic formations in the mid-1700s, notably in his seminal 1761 work De Sedibus et Causis Morborum per Anatomen Indagatis, where he detailed such structures in postmortem examinations, contributing to its establishment in pathological anatomy.[25]Common terms for specific cysts have evolved, often reflecting historical or descriptive origins while undergoing refinement to align with precise pathology. A ganglion cyst is defined as a benign, fluid-filled synovial sac arising from joint or tendon sheaths, typically containing mucoid material and commonly occurring near the wrist.[26] The term "sebaceous cyst," once widely used for common skin cysts filled with keratin, is now considered a misnomer and has been replaced by "epidermoid cyst," as these lesions derive from epidermal cells rather than sebaceous glands; historically, they were known as "wens," an Old English term for subcutaneous lumps dating back to at least the 9th century.[6][27] Similarly, a Baker's cyst, or popliteal cyst, refers to a fluid-filled bulge in the popliteal fossa behind the knee, formed by distension of the gastrocnemius-semimembranosus bursa, named after surgeon William Baker who described it in 1877.[28]Certain uses of "cyst" represent misnomers, particularly in cases where the structure is functional rather than a true pathological sac with an epithelial lining. For instance, many ovarian cysts, such as follicular or corpus luteum cysts, are physiologic formations arising during the menstrual cycle and lack the persistent wall of true cysts, resolving spontaneously without intervention.[29] This distinction highlights the need for accurate nomenclature to prevent diagnostic confusion.Since the 2000s, pathology societies and organizations like the World Health Organization (WHO) have influenced standardization of cystic lesion terminology through updated classifications, emphasizing precise descriptors in reports to improve diagnostic consistency and communication. For example, the WHO's classifications for odontogenic and pancreaticobiliary cysts promote uniform terms to differentiate benign from neoplastic entities, while the Society of Radiologists in Ultrasound has issued consensus guidelines for adnexal cysts to avoid ambiguous phrasing.[30] These efforts build on earlier pathological conventions, reducing reliance on outdated or colloquial names like "sebaceous cyst."
Types Based on Etiology
Cysts are often classified based on their etiology into categories such as congenital, inflammatory, traumatic, neoplastic, and degenerative, providing a framework for understanding their origins based on underlying pathological processes. This classification emphasizes the causative mechanisms rather than anatomical location or histological appearance.Congenital cysts arise from embryonic maldevelopment, where remnants of embryonic structures fail to regress properly during fetal development. For instance, branchial cleft cysts form from incomplete involution of the branchial apparatus, leading to persistent epithelial-lined tracts or cysts in the neck region.[31] These anomalies typically manifest in childhood or early adulthood and are more prevalent in pediatric populations, with certain types like ovarian cysts occurring in approximately 1 in 2,500 live female births.[32]Inflammatory cysts, often retention or inclusion types, develop due to obstruction of glandular ducts or trauma-induced inflammation, resulting in fluid accumulation within dilated spaces. Retention cysts, such as those in salivary glands, occur when mucus buildup from blocked ducts creates pressure and cyst formation, lined by epithelial cells.[33] Post-traumatic inflammatory cysts, like epidermal inclusion cysts, form when skin fragments or epithelial cells are implanted into deeper tissues following injury, leading to a reactive cystic enclosure filled with keratinaceous debris.[34]Neoplastic cysts originate from abnormal cellular proliferation, where benign or malignant tumors develop cystic components due to glandular or secretory activity. Cystadenomas, for example, are benign epithelial neoplasms that produce fluid-filled sacs, commonly in the ovaries, arising from surface epithelial overgrowth without invasive features.[35]Degenerative cysts result from tissue breakdown and wear, often in joint or connective tissues. Synovial cysts, such as those in the lumbar spine, emerge from degeneration of facet joints, where synovial membrane herniates through capsular defects, forming fluid-filled protrusions due to increased jointinstability and inflammation.[36]Rare etiological types include iatrogenic cysts, which form from surgical interventions where epithelial cells or foreign materials are inadvertently implanted, leading to cystic growths like epidermoid cysts in the spinal canal.[37] Parasitic inclusions can also produce cysts, such as hydatid cysts from echinococcal larvae embedding in tissues, creating expansive fluid-filled structures.[38]
Related Structures
Pseudocysts and Similar Lesions
Pseudocysts represent a category of cyst-like lesions characterized by encapsulated fluid collections lacking an epithelial lining, setting them apart from true cysts that possess a defined epithelial wall. These structures arise from various pathological processes, including trauma, inflammation, or leakage of organ-specific fluids, where the surrounding tissues form a confining barrier without regenerating epithelium. The fluid within pseudocysts is typically homogeneous and may contain enzymes, blood, or necrotic debris, depending on the underlying cause.[39][40]A classic example is the pancreatic pseudocyst, which typically forms 4 to 6 weeks following an episode of acute pancreatitis or direct pancreatic injury, as leaked pancreatic enzymes and fluid accumulate and become walled off by adjacent tissues. The formation process involves the progressive organization of inflammatory exudate into a fibrous capsule composed of granulation tissue and collagen, without any epithelial investment—a key contrast to the epithelial-lined structure of true cysts. Similar lesions include urinomas, which develop from urinary tract disruptions such as trauma or obstruction, resulting in extravasated urine encapsulated by reactive fibrous tissue rather than epithelium. Organized hematomas can also evolve into pseudocyst-like formations, particularly in soft tissues or organs like the orbit, where liquefied blood products are enclosed by granulation tissue following initial hemorrhage.[41][40][42]Clinically, pseudocysts carry heightened risks due to their non-epithelial walls, which provide less structural stability than the robust linings of true cysts. In the case of pancreatic pseudocysts, rupture occurs in fewer than 3% of instances, though broader complications including hemorrhage affect 5% to 10% of cases, potentially leading to peritonitis or hemodynamic instability if untreated. This vulnerability underscores the importance of monitoring and intervention for symptomatic or enlarging pseudocysts to mitigate adverse outcomes.[43][44]
Distinctions from Abscesses and Neoplasms
Cysts differ fundamentally from abscesses in their composition and etiology. A cyst is a closed sac lined by epithelium that contains fluid, semi-solid material, or air, and is typically sterile without evidence of active infection or pus formation.[45] In contrast, an abscess represents a localized collection of pus resulting from an acute bacterial infection, featuring neutrophilic infiltrates, surrounding acute inflammation, and often systemic signs of infection such as fever.[46] Abscesses are generally acute processes that develop rapidly and cause significant pain, warmth, and erythema, whereas cysts tend to be chronic, slow-growing, and painless unless secondarily infected.[47]Neoplasms, or tumors, are distinguished from cysts by their cellular characteristics and growth patterns. Cysts are avascular structures with a uniform epithelial lining and lack cellular atypia or uncontrolled proliferation, maintaining a benign architecture on histological examination.[2] Neoplasms, however, consist of abnormal masses of proliferating cells that may exhibit atypia, mitotic activity, and invasive behavior, potentially being benign or malignant.[48] Certain neoplasms can manifest as cystic lesions, such as mucinous cystadenocarcinoma of the ovary or pancreas, which combine a cystic component with neoplastic epithelial elements and require differentiation to avoid undertreatment.[49]Diagnostic challenges arise due to overlapping clinical presentations, including localized pain, swelling, and palpable masses, which can mimic each other across these entities. Historically, before the widespread availability of imaging modalities like ultrasound and CT in the 1950s and 1960s, many cysts were misclassified as neoplasms or abscesses, often necessitating exploratory surgery for definitive diagnosis. While simple cysts are typically benign, further evaluation may be needed in ambiguous cases to rule out neoplasm.[50]
Etiology and Pathogenesis
Developmental and Congenital Causes
Developmental and congenital cysts originate from embryonic remnants or aberrant tissue inclusions that fail to regress during fetal development, leading to fluid-filled sacs present at birth or manifesting shortly thereafter. These anomalies typically arise due to incomplete obliteration of embryonic structures during organogenesis, particularly between weeks 4 and 8 of gestation, when critical fusion and regression processes occur in various organ systems.[51] Genetic mutations can also contribute, disrupting normal developmental pathways and resulting in persistent cystic formations.[52]A prominent example is the thyroglossal duct cyst, which forms from the incomplete involution of the thyroglossal duct—a transient structure that guides the thyroid gland's descent from the foramencecum at the tongue base to its final position in the neck during weeks 4 to 7 of gestation. This cyst accounts for approximately 70% of congenital neck anomalies and has a population prevalence of about 7%, often presenting as a painless midline neck mass that moves with tongue protrusion.[51][53] Similarly, dermoid cysts result from the sequestration of ectodermal elements along embryonic fusion lines, such as during neural tube closure or branchial arch development, leading to benign cysts containing skin appendages like hair or sebaceous glands.[54]Branchial cleft cysts, another common congenital type, stem from failure of the branchial apparatus to fully regress, with second branchial cleft remnants being the most frequent (95% of cases). These are often linked to genetic factors, such as mutations in the EYA1 gene, which is implicated in branchio-oto-renal (BOR) syndrome—an autosomal dominant disorder affecting about 1 in 40,000 individuals and characterized by branchial cysts alongside hearing loss and renal anomalies.[52] In the renal system, autosomal dominant polycystic kidney disease (ADPKD) exemplifies a hereditary congenital cause, where mutations in PKD1 or PKD2 genes lead to cyst formation from dilated renal tubules during early nephrogenesis; cysts are often detectable in utero or childhood, though symptoms like hypertension or pain typically emerge later.[55]Over time, these developmental cysts carry risks of complications, including recurrent infection due to epithelial lining vulnerability and a low potential for malignant transformation, estimated at 1-2% across various types over decades, particularly if untreated. For instance, thyroglossal duct cysts have a 1% risk of papillary thyroidcarcinoma arising within the cyst wall, while unexcised choledochal cysts in the biliary system confer a 10-30% lifetime malignancyrisk, underscoring the importance of monitoring.[56][57]
Acquired Causes
Acquired causes of cysts arise from postnatal environmental, physiological, or pathological processes that disrupt normal tissue architecture, leading to fluid accumulation within encapsulated sacs. Unlike congenital cysts formed during embryonic development, acquired cysts develop later in life through mechanisms such as ductal blockage, mechanical injury, or tissue degeneration, often influenced by systemic factors like hormonal changes or chronic disease. These processes account for the majority of cystic lesions encountered in clinical practice among adults, where cysts frequently remain asymptomatic until enlargement or complications occur.[58]Key mechanisms include ductal obstruction, where calculi or debris block glandular ducts, causing upstream dilation and cyst formation; for instance, sialolithiasis in salivary glands leads to saliva stasis and secondary cystic expansion due to retained secretions.[59]Trauma can induce cysts by damaging tubular or ductal structures, resulting in localized fluid collections; post-injury epididymal cysts form from epididymal tubule dilation and serous fluid accumulation following scrotal trauma.[60] Degenerative processes, such as hormonal imbalances, contribute to cyst development by altering cellular function and promoting follicular persistence; ovarian cysts often emerge from prolonged estrogen stimulation, preventing normal corpus luteum regression and leading to fluid-filled structures.[29][61]Risk factors for acquired cysts encompass age-related changes, endocrine influences, and iatrogenic events. Advancing age increases susceptibility, with hepatic cysts showing a prevalence of up to 27% in individuals over 50 years due to cumulative degenerative effects on biliary epithelium. Endocrine factors, particularly estrogen excess, elevate risk in estrogen-sensitive tissues; breast cysts are more common in premenopausal women owing to cyclical hormonal fluctuations that promote ductal ectasia and fibrosis. Iatrogenic causes include radiation exposure, which can trigger cystic degeneration through vascular damage and necrosis; post-radiation cysts have been documented in up to 10-20% of pediatric brain tumor survivors years after therapy.[62][63]Acquired cysts represent a significant portion of adult cystic presentations, with simple renal cysts alone affecting 11.5% of individuals aged 50-70 and hepatic cysts occurring in 15-18% of the general population on imaging. Growth rates vary but are typically slow, with some hepatic cysts expanding by 1-5 mm annually, though accelerated progression up to 20-25% per year can occur in hormonally influenced cases like polycystic liver disease during pregnancy. Non-infectious inflammation plays a crucial role in cyst wall stabilization, where chronic low-grade responses lead to periductal fibrosis; this fibrous encapsulation, as seen in breast fibrocystic changes, results from repeated stromal remodeling without microbial involvement, forming a collagen-rich barrier around the cystic lumen.[64][65][66][67]
Cysts by Anatomic Location
Reproductive System
In the female reproductive system, cysts primarily affect the ovaries and are often linked to the hormonal dynamics of the menstrual cycle. Functional cysts, including follicular and corpus luteum types, represent the most common variants and arise as part of normal ovarian physiology. Follicular cysts form when a dominant follicle fails to rupture during ovulation, resulting in continued enlargement driven by gonadotropin stimulation. Corpus luteum cysts develop post-ovulation from the luteinized follicle remnant, which may accumulate serous fluid or blood if pregnancy does not occur. These cysts typically resolve spontaneously within 1 to 3 months without intervention. They affect approximately 8 to 10% of women during reproductive years.[29][68]Pathological cysts in females include endometriomas, commonly referred to as chocolate cysts due to their thick, dark brown, tar-like contents derived from degraded blood products. These form when ectopic endometrial tissue implants on the ovarian surface during endometriosis, leading to cyclic bleeding and encapsulation within a fibrotic wall. Endometriomas indicate moderate to severe endometriosis and can impair fertility by distorting ovarian architecture.[69][70]In the male reproductive system, cysts commonly involve the epididymis or prostate. Spermatoceles are benign, fluid-filled dilatations of the epididymal tubules containing spermatozoa, typically arising from obstruction or trauma to the ductal system. They are asymptomatic in most cases and occur in about 30% of asymptomatic adult males on ultrasound evaluation, with increased prevalence following vasectomy due to post-procedural ductal distension. Prostatic utricular cysts originate as congenital remnants of the Müllerian duct, remaining latent until adulthood when they may enlarge and cause symptoms such as recurrent urinary tract infections, hematuria, or ejaculatory dysfunction through compression of adjacent structures. Their incidence is approximately 1% in adult autopsies, though symptomatic cases are rarer.[71][72]The formation of reproductive cysts frequently stems from hormonal influences that promote fluid retention or tissue proliferation. In ovarian functional cysts, imbalances in follicle-stimulating hormone and luteinizing hormone during the menstrual cycle prevent normal follicular regression, allowing persistent growth. This retention can lead to complications like ovarian torsion, where the ovary twists on its vascular pedicle, with an estimated risk of 1 to 2% among women with adnexal cysts, particularly those exceeding 5 cm in diameter.[29][73]Reproductive cysts are more prevalent in females than males, reflecting the role of cyclic hormonal activity in ovarian pathology. Women face a lifetime risk of approximately 25% for developing an ovarian cyst, with higher incidence during reproductive years due to repeated ovulatory events.[74]
Cutaneous and Subcutaneous Tissues
Cysts arising in the cutaneous and subcutaneous tissues represent a significant portion of benign skin lesions, primarily originating from epidermal or adnexal structures such as hair follicles and sebaceous glands. The most common type is the epidermoid cyst, which accounts for approximately 80% of follicular skin cysts and forms from the accumulation of keratin-producing epidermal cells trapped within the dermis.[75] Pilar cysts, also termed trichilemmal cysts, derive from the outer root sheath of hair follicles and are particularly prevalent on the scalp, comprising a notable subset of these lesions.[9] Dermoid cysts, in contrast, are congenital and contain diverse ectodermal elements like hair, sebaceous glands, and sweat glands, distinguishing them from the more uniform keratin-filled epidermoid and pilar variants.[54]Pathogenesis of these cysts typically involves occlusion of the follicular infundibulum, leading to retention of keratin and cellular debris, or results from traumatic implantation of epidermal elements into deeper tissues.[6] They generally range from 0.5 to 5 cm in size and present as firm, mobile, subcutaneous nodules with a central punctum in epidermoid cases.[76] A hallmark feature is the presence of laminated keratin within the cyst cavity, which yields a thick, cheesy material upon surgical incision or rupture; such rupture often provokes a marked inflammatory reaction due to leakage of contents into surrounding tissues.[5] For dermoid cysts, the developmental entrapment of multipotent ectodermal cells during embryogenesis underpins their formation, potentially along embryonic fusion lines.[54]Epidemiologically, cutaneous cysts affect at least 20% of adults, with epidermoid cysts most frequently occurring in young to middle-aged individuals and showing a twofold higher incidence in men compared to women.[77][76] These lesions are more common in areas subject to friction or trauma, such as the back, neck, and trunk, though pilar cysts predominate on the scalp.[76] Pilar cysts occur in fewer than 10% of the population overall but represent a leading cyst type in hairy regions.[9]
Head, Neck, and Central Nervous System
Cysts in the head, neck, and central nervous system (CNS) primarily arise from developmental remnants or meningeal abnormalities, often presenting as benign, fluid-filled lesions that may remain asymptomatic unless they exert mass effect on adjacent structures. In the neck, thyroglossal duct cysts represent the most prevalent congenital midline anomaly, accounting for up to 70% of such lesions, and originate from the persistent epithelial remnants of the thyroglossal duct that fail to involute during embryonic development. These cysts typically manifest as painless, mobile masses near the hyoid bone, with approximately 25-40% developing secondary infection, leading to inflammation and potential abscess formation. Branchial cleft cysts, conversely, occur laterally and are the second most common congenital neck cysts, with those derived from the second branchial arch comprising 40-95% of cases; they form due to incomplete obliteration of embryonic branchial apparatus structures, often appearing as fluctuant masses anterior to the sternocleidomastoid muscle.Within the CNS, arachnoid cysts are benign, non-neoplastic collections of cerebrospinal fluid (CSF) encased by arachnoid membranes, with an estimated incidence of about 1% among intracranial lesions, though post-2010 MRI studies in asymptomatic adults report a prevalence of 1.4%. These cysts result from CSF accumulation in duplicated or split arachnoid layers, frequently located in the middle cranial fossa, and are often incidental findings, with symptoms emerging only in cases of significant expansion. Colloid cysts, located in the anterior third ventricle at the foramen of Monro, arise from endodermal remnants and contain thick, mucoid material rather than CSF; while rare, they carry a notable risk of obstructive hydrocephalus in approximately 10-60% of symptomatic presentations, depending on size and position, potentially causing sudden neurological deterioration.Pathophysiologically, head and neck cysts like thyroglossal and branchial types persist from embryonic ductal or cleft remnants that trap epithelial cells and secretions, fostering gradual enlargement, whereas CNS cysts such as arachnoid and colloid varieties involve CSF or proteinaceous fluid buildup within meningeal or ventricular spaces, leading to compressive effects. Clinical manifestations typically remain subclinical until cysts exceed 2 cm, at which point mass effect may induce symptoms including dysphagia from pharyngeal compression in neck lesions or seizures and headaches from intracranial pressure in CNS cases. Advancements in MRI since 2010 have enhanced detection of these asymptomatic cysts, revealing their true prevalence and underscoring the importance of serial imaging for monitoring growth in high-risk locations like the third ventricle.
Thoracic and Abdominal Organs
Cysts in the thoracic cavity primarily include bronchogenic and pericardial variants, which are congenital anomalies arising during embryonic development. Bronchogenic cysts originate from abnormal budding of the primitive foregut between the third and sixth weeks of gestation, resulting in fluid-filled sacs lined by respiratory epithelium and typically located in the mediastinum.[78] These lesions are rare, with an estimated incidence of 1 in 42,000 to 68,000 live births, and account for approximately 0.5% to 1% of all mediastinal masses in adults.[79] They are often asymptomatic and discovered incidentally on imaging, but larger cysts (>5 cm) may compress adjacent structures, leading to symptoms such as dyspnea, chest pain, or recurrent infections. Pericardial cysts, another rare thoracic entity, form from incomplete fusion of mesenchymal lacunae in the pericardium during embryogenesis and are estimated to occur in 1 in 100,000 individuals.[80] These benign, fluid-filled sacs are usually right-sided and asymptomatic, though compressive effects on the heart or lungs can rarely cause cough, palpitations, or right ventricular outflow obstruction.[81]In the abdominal cavity, cysts commonly affect the liver, pancreas, and kidneys, often presenting as incidental findings on routine imaging. Simple hepatic cysts are benign, fluid-filled lesions derived from aberrant intrahepatic biliary ducts that fail to connect to the biliary tree, with a pathophysiology involving congenital malformation rather than acquired obstruction in most cases.[65] Their prevalence increases with age, affecting 3% to 5% of the general adult population on ultrasound and up to 15% on computed tomography, with simple cysts found in approximately 5% of adults over 40 years and often detected incidentally during evaluations for unrelated conditions.[82] Recent ultrasound screening studies from the 2020s report a prevalence of approximately 22% in adults, increasing to 29–34% in elderly individuals over 60, particularly women, highlighting the role of widespread imaging in identifying these lesions.[83] Complications arise when cysts grow large (>10 cm), potentially causing biliary obstruction and jaundice through extrinsic compression of the extrahepatic bile ducts.[84]Pancreatic cysts, such as serous cystadenomas, are typically benign multicystic neoplasms composed of numerous small cysts (<2 cm) filled with serous fluid, arising from the ductal epithelium and more prevalent in women over 60 years.[85] These lesions account for 16% to 33% of pancreatic cystic neoplasms and are often incidental, though their expansion can lead to pancreatitis via ductal obstruction or local inflammation.[86] The overall malignant risk for pancreatic cysts is estimated at 5% to 8% over 5 to 10 years of follow-up, though serous variants have a very low transformation rate (<1%), with higher risks associated with mucinous or intraductal papillary mucinous neoplasms.[87] Simple renal cysts, meanwhile, develop from tubular epithelial outpouchings in the nephrons and are the most common abdominal renal lesions, with a prevalence of about 25% in adults over 40 years and rising to 50% in those over 50, where approximately half are bilateral.[19] These cysts rarely cause dysfunction but can contribute to hematuria or hypertension if complicated by hemorrhage or infection. Pathophysiologically, many abdominal cysts, including hepatic and biliary variants, may involve mesenchymal rests—embryonic remnants that fail to regress—leading to cystic dilation, while acquired mechanisms like trauma can exacerbate growth in predisposed individuals.[88] Diagnosis often relies on abdominal imaging modalities, such as ultrasound or MRI, to characterize these lesions and assess for complications like organ dysfunction.[82]
Musculoskeletal System
Cysts within the musculoskeletal system primarily affect bones, joints, and surrounding soft tissues, often arising from degenerative, traumatic, or developmental processes that lead to fluid accumulation and structural weakening. These lesions can compromise mobility and stability, with bone cysts like aneurysmal and unicameral types posing risks of pathologic fracture, while joint-related cysts such as ganglia and Baker's cysts contribute to pain and functional limitations in affected extremities.[89][90]In bone, aneurysmal bone cysts (ABCs) are expansile, eccentric lesions predominantly occurring in children and adolescents under 20 years of age, accounting for 1.4-2.3% of primary bone tumors. These vascular malformations typically involve the metaphysis of long bones, presenting with pain, swelling, and rapid expansion due to blood-filled cavities separated by fibrous septa. Unicameral bone cysts, also known as simple bone cysts, are benign, fluid-filled cavities most commonly located in the metaphysis of the proximal humerus or femur in children and adolescents, remaining asymptomatic until a pathologic fracture occurs, at which point localized pain and tenderness manifest.[91][92][89][93]Joint and soft tissue cysts include ganglion cysts, which represent 60-70% of hand and wrist soft-tissue masses and arise from synovial herniation or degeneration, with approximately 70% occurring on the dorsal aspect of the wrist. These translucent, mucin-filled sacs connect to underlying joint capsules or tendon sheaths, often causing discomfort during wrist motion. Baker's cysts, or popliteal cysts, form in the posterior knee from fluid distension of the gastrocnemius-semimembranosus bursa, frequently associated with underlying knee osteoarthritis, leading to a visible bulge and sensations of tightness or fullness.[26][94][95][96]Pathogenesis of these cysts often involves degenerative leakage of joint fluid into surrounding tissues or intraosseous hemorrhage, as seen in osteoarthritis-related subchondral cysts where synovial fluid intrudes through articular defects, or in ABCs where vascular proliferation and bleeding contribute to cystic expansion. Unicameral cysts may result from venous obstruction or fluid accumulation within bone marrow, while ganglion and Baker's cysts stem from increased intra-articular pressure forcing synovial fluid outward. ABCs exhibit rapid growth, potentially expanding several centimeters in months, with a pathologic fracture risk elevated in long bones like the humerus due to cortical thinning.[97][98][91]Recent radiological classifications in the 2020s emphasize distinguishing aggressive from non-aggressive variants of bone cysts through imaging features such as cortical ballooning, matrix mineralization, and periosteal reaction, aiding in prognostic assessment and treatment planning for lesions like ABCs.[99]
Infectious Cysts
Protozoal and Bacterial Origins
Protozoal infections can lead to the formation of cysts through intracellular parasitism, where the organisms encyst to evade host immunity and ensure long-term survival. Toxoplasma gondii, an obligate intracellular protozoan, is a primary example, establishing latent tissue cysts primarily in the brain, skeletal muscle, and occasionally the heart and eyes of infected hosts.[100] These cysts contain bradyzoites, a dormant stage of the parasite that forms within host cells to resist immune clearance and proteolytic degradation, allowing persistence for the host's lifetime in immunocompetent individuals.[101] In such hosts, latent infection is common, with global seroprevalence estimated at approximately 30%, affecting over 2 billion people worldwide, particularly in regions with poor sanitation and high exposure to feline feces or undercooked meat.[102] However, in immunocompromised patients, such as those with AIDS (CD4 counts below 100 cells/μL), reactivation of these cysts can occur, leading to rupture and dissemination of tachyzoites, which cause necrotizing encephalitis with ring-enhancing lesions mimicking cystic tumors on imaging.[103]Another protozoan, Entamoeba histolytica, contributes to cystic-like lesions through extraintestinal invasion, most notably forming amebic liver abscesses that often present as solitary, well-defined cystic structures on ultrasound or CT, filled with anchovy-paste-like necrotic debris.[104] This occurs when trophozoites migrate hematogenously from the intestinal lumen to the liver, inducing tissue destruction and liquefaction without a true fibrous capsule, distinguishing it from bacterial abscesses but frequently misdiagnosed as pyogenic cysts or malignancies due to its imaging appearance.[105] Transmission via cyst-contaminated water or food is prevalent in endemic tropical areas, with an estimated 50 million symptomatic cases annually, though liver involvement represents only 1-3% of invasive disease.[106] Pathogenesis involves host cytokine-mediated necrosis rather than encystment, but the resulting abscess cavities function similarly to cysts in containing the infection.[107]Bacterial origins of cysts are less common and typically arise from walled-off abscesses rather than true encystment, serving as survival niches for pathogens in chronic infections. Mycobacteria, particularly Mycobacterium tuberculosis, cause scrofula (cervical tuberculous lymphadenitis), where caseating granulomas in neck lymph nodes evolve into cold abscesses—avascular, fluctuant collections lacking acute inflammatory signs—that can liquefy and form cystic cavities if untreated.[108] These structures encapsulate acid-fast bacilli, promoting dormancy and preventing systemic spread, with higher incidence in endemic tuberculosis regions affecting up to 40% of extrapulmonary cases.[109] Similarly, rare staphylococcal infections, such as those from Staphylococcus aureus, can lead to retention cysts in soft tissues, where bacterial biofilms within pre-existing cysts or sinuses cause chronic suppuration and encapsulation, often following incomplete drainage of furuncles or carbuncles.[110] These bacterial cysts emphasize extracellular mechanisms, with pus accumulation walled off by host fibroblasts to localize infection.[111]Diagnosis of protozoal and bacterial cysts relies heavily on serologic testing, alongside imaging and histopathology. For T. gondii, IgG seropositivity indicates past exposure and latency, with rates reaching 80% in high-prevalence areas like parts of Latin America, confirming chronic cyst presence; IgM detects acute infection, while PCR on cyst fluid verifies bradyzoites.[112] Amebic serology shows anti-lectin IgG in over 90% of liver abscess cases, aiding differentiation from bacterial mimics.[104] Bacterial cysts require acid-fast staining for mycobacteria or Gram-positive cocci identification for staphylococci, with culture yielding definitive results despite frequent negativity in chronic forms.[108] Global epidemiology underscores higher risks in developing regions, where T. gondii exposure exceeds 1 billion lifetime infections, driving reactivation in HIV-endemic populations.[113]
Parasitic and Fungal Cysts
Parasitic cysts arise from helminth infections, particularly those involving larval stages that encyst within host tissues, leading to chronic granulomatous responses and potential complications due to long-term persistence. Echinococcosis, caused by the larval stage of Echinococcus granulosus, manifests primarily as hydatid cysts in the liver (65-75% of cases) and lungs (15-20%), accounting for approximately 90% of hydatid cyst locations in humans.[114] These unilocular cysts form through the ingestion of eggs, followed by larval hatching in the intestine, hematogenous dissemination, and encystment in target organs, where protoscolices (infective larval heads) develop within the cyst fluid, known as hydatid sand.[115] The host mounts a fibrous capsule around the cyst, enabling chronicity that can last decades, with interactions involving immune evasion by the parasite's laminated layer and periodic release of antigens that sustain low-grade inflammation.[116]Rupture of hydatid cysts poses a severe risk, potentially spilling protoscolices and cyst fluid into surrounding tissues or bloodstream, triggering severe allergic reactions, including anaphylactic shock due to hypersensitivity to parasite antigens, reported in 1-12.5% of rupture cases, while minor reactions occur in up to 25% in some series.[117] Another significant helminthic cause is cysticercosis from Taenia solium, where ingested eggs hatch into larvae that encyst in the central nervous system, forming neurocysticercosis cysts that are estimated to affect 2.56 to 8.30 million people globally, including symptomatic and asymptomatic cases, predominantly in endemic regions of Latin America, Asia, and Africa.[118] Pathogenesis involves larval invasion of brain parenchyma, evoking a Th2-biased immune response that leads to cyst viability for years, followed by degeneration and calcification in chronic stages, with calcified dead cysts observed in about 30-40% of resolved cases, contributing to epilepsy through perilesional gliosis.[119] These parasitic cysts highlight host-parasite dynamics where encystment promotes survival, but eventual host immunity or spontaneous death results in fibrotic or calcified remnants, underscoring the chronic nature of these infections.Fungal cysts, though less common, emerge from dimorphic fungi that form encapsulated structures in immunocompromised hosts, often evolving from granulomatous reactions. Cryptococcosis, primarily due to Cryptococcus neoformans, produces gelatinous pseudocysts in the brain and pulmonary tissues, particularly in HIV/AIDS patients or other immunocompromised individuals, where inhaled yeast disseminates hematogenously and elicits a minimal inflammatory response, allowing cystic masses filled with gelatinous mucoid material containing encapsulated yeasts.[120] These pseudocysts, visible on imaging as soap-bubble lesions, reflect chronic persistence facilitated by the fungus's polysaccharide capsule, which inhibits phagocytosis and promotes intracellular survival within macrophages, leading to slowly expanding lesions that can cause mass effect or meningitis.[121]In histoplasmosis caused by Histoplasma capsulatum, initial pulmonary granulomas form in response to inhaled conidia, which convert to yeast forms and disseminate, particularly in chronic or disseminated cases among immunocompromised hosts; these granulomas can evolve into cystic structures through central necrosis and cavitation, as seen in chronic cavitary pulmonary histoplasmosis, where fibrotic walls encapsulate residual fungal elements.[122] The pathogenesis involves a robust cell-mediated immune response that confines the fungus but allows for chronic evolution, with cystic granulomas persisting as calcified or cavitary foci in up to 5-10% of heavy-exposure cases, emphasizing the role of host immunity in containing rather than eradicating the infection.[123]Recent advances in parasitic cyst management include vaccine trials for echinococcosis in the 2020s, such as the EG95 recombinant antigen vaccine administered to sheep in endemic sheep-rearing regions like Argentina and Australia, which has demonstrated up to 95% efficacy in preventing cyst formation and reduced disease incidence by 30-90% in vaccinated flocks, thereby interrupting transmission cycles to humans. As of 2025, nanoparticle-based EG95 vaccines have shown promising adjuvanticity in preclinical studies, enhancing immune responses.[124][125][126] These interventions highlight targeted prophylaxis in animal reservoirs to mitigate human chronicity.
Neoplastic Cysts
Benign Cystic Neoplasms
Benign cystic neoplasms are non-cancerous growths characterized by the proliferation of epithelial or lymphatic tissues forming fluid-filled cysts, distinct from inflammatory or developmental cysts due to their neoplastic origin. These lesions arise from abnormal cell growth but lack invasive potential, often presenting as incidental findings or causing symptoms from mass effect. Common examples include serous cystadenomas, which develop from serous epithelial cells, and lymphangiomas, which originate from malformed lymphatic vessels.[35][127][128]Serous cystadenomas are among the most frequent benign cystic neoplasms, occurring primarily in the ovary and pancreas. In the ovary, they typically manifest as multicystic lesions with sizes ranging from small nodules to large masses up to 20-30 cm, often unilateral but bilateral in 10-20% of cases, and account for approximately 16% of all ovarian epithelial neoplasms. Pancreatic serous cystadenomas, conversely, are rarer, comprising about 1% of pancreatic neoplasms and 20-33% of cystic pancreatic lesions, usually presenting as microcystic or honeycomb-patterned structures averaging 2-4 cm, though larger variants exist, predominantly in women around age 58. Lymphangiomas, particularly mesenteric types, are compressible, multiloculated cystic masses that primarily affect children, with over 50% diagnosed before age 5 and an incidence of about 1 in 250,000 live births; they represent less than 1% of all lymphangiomas but can cause abdominal distension or obstruction due to their location in the mesentery.[35][129][130][131][132][128]Pathogenetically, these neoplasms involve benign epithelial hyperplasia leading to cystic dilation, where serous cystadenomas derive from fallopian tube-like epithelium forming serous-lined cysts filled with clear fluid, without atypical features or invasion. Lymphangiomas result from congenital maldevelopment of lymphatic channels, forming dilated, endothelium-lined spaces rather than true epithelial proliferation. Surgical resection is curative with low recurrence rates, typically under 5% for completely excised benign lesions, as these tumors do not metastasize or recur in the residual tissue. Imaging characteristically reveals thin-walled cysts without solid nodules or septations greater than 3 mm, aiding differentiation from malignant counterparts; for ovarian serous cystadenomas, ultrasound or MRI shows unilocular or oligolocular structures with the "beak sign" at pedicle attachment.[127][130][133][134][129]Recent molecular studies since 2015 have identified KRAS mutations in some benign cystic neoplasms, such as mucinous cystadenomas associated with ovarian or pancreatic lesions, occurring in up to 37% of non-malignant cases without progression to carcinoma, highlighting potential early proliferative events that do not confer malignancy. These findings underscore gaps in understanding driver mutations in purely benign entities, as opposed to their higher prevalence in borderline or malignant transitions.[135]
Malignant Cystic Tumors
Malignant cystic tumors represent a subset of cystic neoplasms that exhibit invasive behavior and potential for metastasis, distinguishing them from their benign counterparts through progressive dysplastic alterations in the epithelial lining. These tumors arise primarily in organs such as the ovary and pancreas, where cystic structures harbor malignant transformation risks. In the ovary, mucinous cystadenocarcinomas constitute approximately 3-5% of all epithelial ovarian malignancies, often presenting as large, multiloculated cysts with solid components indicative of invasion.[136] Similarly, in the pancreas, intraductal papillary mucinous neoplasms (IPMNs) account for approximately 5-10% of pancreatic neoplasms, with about 30% of resected IPMNs demonstrating an invasive component upon pathological examination.[137][138]The pathogenesis of these tumors involves sequential dysplastic changes in the cyst lining epithelium, progressing from low-grade dysplasia to high-grade dysplasia and ultimately stromal invasion, driven by genetic mutations such as KRAS and GNAS in IPMNs. This malignant evolution enables local spread and distant metastasis, with tumor markers like CA 19-9 often elevated in up to 80% of invasive cases, serving as a serological indicator of progression. In ovarian mucinous cystadenocarcinomas, similar epithelial atypia leads to peritoneal dissemination, while pancreatic IPMNs may invade the ductal system and parenchyma. Cyst fluid analysis plays a crucial role in risk stratification, evaluating markers such as carcinoembryonic antigen (CEA) levels above 192 ng/mL, which correlate with mucinous histology and higher malignancy risk, alongside molecular profiling for mutations to predict invasive potential.[139][140]00248-8/fulltext)Staging for malignant cystic tumors follows organ-specific systems, such as FIGO for ovarian cancers and TNM for pancreatic, emphasizing early detection to improve outcomes. For early-stage invasive IPMNs post-resection, 5-year survival rates range from 40-60%, significantly better than the <10% for advanced pancreatic ductal adenocarcinomas due to the often slower growth of cystic variants. Prognostic factors include cyst size greater than 3 cm, mural nodules, and main duct involvement, which elevate the risk of invasion and guide surgical decisions. Recent updates in international guidelines, such as the 2024 Kyoto guidelines, refine surveillance protocols for high-risk cystic neoplasms by incorporating cyst fluid analysis and imaging, improving risk assessment and avoidance of overtreatment in low-progression cases.[141][142][143]
Diagnosis
Clinical Evaluation and Symptoms
Cysts frequently present asymptomatically and are discovered incidentally during routine physical examinations or imaging for unrelated conditions, with the majority remaining undetected unless they grow large or cause complications. For instance, most ovarian cysts are asymptomatic, identified during pelvic exams or ultrasonography. Similarly, over 94% of intracranial arachnoid cysts do not produce symptoms. Symptomatic cysts may manifest with pain due to expansion or rupture, mass effect leading to compression of adjacent structures, or organ dysfunction; examples include jaundice from biliary obstruction by choledochal cysts or hematuria in cases of renal cysts causing urinary tract involvement.Clinical evaluation begins with a detailed patient history to identify potential risk factors and guide further assessment. Relevant inquiries include family history, which is a key risk factor for hereditary conditions like autosomal dominant polycystic kidney disease. Prior trauma may be associated with the development of certain cysts, such as those in the musculoskeletal system. Red flags suggestive of underlying malignancy include unexplained weight loss, rapid lesion growth, or persistent symptoms unresponsive to conservative measures.The physical examination focuses on localizing and characterizing the cyst through non-invasive techniques. Palpation assesses for fluctuance, a sign of fluid content, and mobility, which can indicate attachment to surrounding tissues. Transillumination, where light is shone through the lesion, helps differentiate simple fluid-filled cysts from solid masses, as clear fluid allows light transmission in superficial locations like the neck or scrotum. Location-specific findings may include a palpable pelvic mass for ovarian cysts or tenderness over the affected area in abdominal presentations.Patient demographics influence the clinical suspicion for cysts. Age and gender correlations are notable; for example, simple renal cysts increase in prevalence with advancing age, while ovarian cysts warrant heightened concern for malignancy in postmenopausal women due to elevated risk.
Imaging Modalities
Ultrasound serves as the first-line imaging modality for detecting and characterizing many cysts due to its accessibility, lack of ionizing radiation, and ability to provide real-time visualization. It exhibits approximately 90% sensitivity and specificity for identifying simple cysts, such as hepatic ones, appearing as homogeneously anechoic structures with thin walls and no internal echoes.[144] For superficial and abdominal cysts, ultrasound is particularly cost-effective and portable, enabling quick assessment in outpatient settings without the need for contrast agents.[145] Doppler ultrasound enhances characterization by evaluating vascularity; avascular simple cysts suggest benignity, while increased flow in walls or septa may indicate complexity or inflammation.[146] Limitations include operator dependence and reduced efficacy in obese patients or deep-seated lesions, where acoustic shadowing from calcifications can obscure details.[147]Computed tomography (CT) and magnetic resonance imaging (MRI) are employed for complex cysts requiring detailed anatomic evaluation, especially when ultrasound is inconclusive. The Bosniak classification system, updated in 2019, stratifies renal cysts into categories I through IV based on CT or MRI features like wall thickness, septa, calcifications, and enhancement, guiding malignancy risk assessment from benign (category I) to highly suspicious (category IV).[148] MRI offers superior soft-tissue contrast for central nervous system (CNS) cysts, such as arachnoid cysts, delineating cyst contents from surrounding brain tissue without radiation exposure and aiding in differential diagnosis from neoplasms or infections.[149] Advantages of these modalities include multiplanar imaging and contrast enhancement to detect subtle solid components, but limitations encompass higher costs, radiation in CT, and contraindications like claustrophobia or metal implants in MRI.[150]Advanced techniques provide targeted evaluation for specific cyst locations. Endoscopic ultrasound (EUS) excels in gastrointestinal cysts, combining endoscopy with high-frequency ultrasound to assess mural involvement, cyst wall integrity, and fine-needle aspiration feasibility, distinguishing cystic from solid lesions with high resolution.[151] Positron emission tomography (PET), often fused with CT, aids in neoplastic suspicion by detecting metabolic activity; 18F-FDG uptake in cyst walls or nodules helps differentiate malignant from benign pancreatic cysts, though false positives can occur in inflammatory cases.[152] These methods improve specificity in challenging anatomies but are invasive (EUS) or expensive (PET), limiting routine use.Since 2020, artificial intelligence (AI)-assisted imaging has enhanced cyst evaluation, particularly for malignancy prediction in pancreatic cysts, with models achieving up to 20% higher sensitivity in detecting high-risk lesions compared to traditional guidelines.[153] AI integrates radiomic features from ultrasound, CT, or MRI to automate classification, reducing interobserver variability and improving specificity by analyzing subtle patterns like texture and enhancement.[154] While promising for risk stratification, AI tools require validation across diverse populations and integration with clinical workflows to address limitations like data bias.[155]
Pathological Confirmation
Pathological confirmation of cysts typically requires biopsy techniques to obtain fluid or tissue samples for detailed analysis, often guided by prior imaging to target suspicious areas. Fine-needle aspiration (FNA) is a common initial method, involving the insertion of a thin needle to extract cyst fluid, achieving approximately 85% accuracy in distinguishing benign from malignant cystic lesions, particularly in head and neck cases.[156] For cysts containing solid components, core biopsy is recommended, using a larger needle to procure tissue cores that provide more architectural detail and higher diagnostic yield compared to FNA alone.[157]Analysis of aspirated cyst fluid plays a central role in characterization. Cytological examination of the fluid assesses for cellular atypia, inflammation, or malignant cells, aiding in the identification of neoplastic potential.[158] Biochemical evaluation includes measuring amylase levels, where elevated concentrations (often >250 U/L) indicate communication with the pancreatic duct, as seen in pseudocysts.[159] Tumor markers such as carcinoembryonic antigen (CEA) are also quantified; levels exceeding 192 ng/mL in cyst fluid strongly suggest a mucinous neoplasm, with high specificity for differentiating mucinous from non-mucinous cysts.[160]If tissue is obtained via core biopsy or subsequent excision, histopathology provides definitive insights into cyst architecture. Routine staining, such as hematoxylin and eosin, reveals the epithelial lining type—ranging from squamous to cuboidal or columnar—distinguishing true cysts from pseudocysts lacking an epithelial layer.[161] Immunohistochemical markers like Ki-67 quantify proliferative activity in the lining epithelium, with elevated expression indicating higher risk of malignancy in neoplastic cysts.[162] However, sampling errors can occur in up to 10% of cases, leading to inadequate or non-representative specimens that may underestimate pathology.[163]Recent advancements address diagnostic gaps through molecular testing on cyst fluid or tissue. For instance, detection of GNAS mutations is highly specific for intraductal papillary mucinous neoplasms (IPMNs), integrated into management guidelines since 2018 to refine risk stratification when cytology is inconclusive.[164]
Treatment and Management
Observation and Monitoring
Observation and monitoring, also known as watchful waiting, is the preferred approach for asymptomatic or low-risk cysts that do not require immediate intervention, allowing for periodic assessment to detect any changes without unnecessary procedures.[165] This strategy is particularly applicable to simple cysts measuring less than 3 cm in diameter with no associated symptoms, such as renal cysts classified under Bosniak category I, which are universally regarded as benign and warrant indefinite observation without routine follow-up imaging.[166] For these low-risk lesions, confirmed through initial diagnostic evaluation, the focus is on avoiding overtreatment while ensuring patient reassurance. Under the Bosniak 2019 classification, low-risk categories (I and II) exhibit negligible malignancy risk (<1%), supporting conservative management.[167]Standard protocols for monitoring involve serial imaging, typically with ultrasound performed every 6 to 12 months to evaluate size, morphology, and any new features suggestive of progression. Growth thresholds, such as a more than 20% increase in cyst diameter or the development of complex features, serve as key indicators to escalate care, potentially prompting advanced imaging or specialist consultation.[168] These intervals may be adjusted based on patient factors like age and comorbidities, with transitions to less frequent checks or pure watchful waiting if stability is confirmed over time.[165]Outcomes of observation demonstrate high stability for benign cysts, with 80-90% remaining unchanged or even regressing during long-term follow-up, minimizing risks associated with invasive management.[169]Patient education is integral, emphasizing recognition of warning signs such as flank pain, hematuria, or fever, which should prompt immediate medical attention.[170] Evidence from guidelines and studies supports the safety of this approach for over 95% of non-neoplastic cysts, significantly reducing overtreatment rates while maintaining effective surveillance.[165] A 2022 meta-analysis on the Bosniak classification further validates that low-risk categories exhibit negligible malignancy progression under monitoring, affirming its role in clinical practice.[171]
Minimally Invasive Interventions
Minimally invasive interventions for cysts primarily involve percutaneous or endoscopic techniques aimed at drainage, sclerosis, or ablation, particularly for patients at high surgical risk due to comorbidities. These approaches are indicated for symptomatic or recurrent cysts where observation has failed, offering reduced recovery time compared to open procedures.Aspiration combined with sclerotherapy is a common percutaneous method for managing recurrent simple cysts, such as renal cysts, using agents like ethanol to induce epithelial fibrosis and prevent fluid reaccumulation. For renal cysts, ethanol sclerotherapy achieves success rates of 70-95%, defined as significant volume reduction (>50%) and symptom relief. Recurrence rates following aspiration-sclerotherapy range from 10-30%, lower than the 30-70% seen with aspiration alone, though multiple sessions may be required for optimal outcomes. This technique is typically performed under ultrasound or CT guidance as an outpatient procedure.Endoscopic interventions, such as cystogastrostomy guided by endoscopic ultrasound (EUS), are effective for pancreatic pseudocysts, creating a drainage pathway into the stomach. EUS-guided cystogastrostomy yields resolution rates of 80-95% in suitable cases, with clinical success often sustained long-term and comparable to surgical drainage but with shorter hospital stays. These procedures are preferred for cysts adjacent to the gastrointestinal tract, allowing direct access without external incisions.Complications of these interventions are infrequent but include infection in approximately 1-5% of cases and bleeding or hemorrhage in 2-5%, potentially requiring additional management. Patient selection is crucial; procedures should be avoided or approached cautiously in individuals with coagulopathy or active anticoagulation, as these increase bleeding risks, necessitating correction of coagulation parameters beforehand.Recent advances in ablation techniques, such as radiofrequency ablation (RFA) for hepatic cysts, have shown promising volume reductions in treated lesions, with ongoing trials evaluating long-term efficacy and safety in non-surgical candidates.
Surgical and Pharmacological Approaches
Surgical excision remains a cornerstone for managing symptomatic cysts, particularly when conservative measures fail or complications arise. For benign ovarian cysts, laparoscopic excision is preferred due to its minimally invasive nature, offering high success rates of approximately 94% in achieving complete removal without conversion to open surgery.[172] This approach minimizes postoperative pain, shortens recovery time, and preserves ovarian function in most cases. In contrast, fenestration is commonly employed for arachnoid cysts, involving the creation of an opening in the cyst wall to allow cerebrospinal fluid drainage; this procedure yields cyst volume reductions of 58-74% and symptom improvement in 80-97% of patients, depending on the technique used.[173][174]Pharmacological interventions target specific cyst etiologies, providing non-surgical options for definitive management in select cases. For hydatid cysts caused by Echinococcus granulosus, albendazole serves as the primary anti-parasitic agent, administered at 10-15 mg/kg daily in cycles of 3 months; it induces cyst shrinkage in 20-60% of cases and reduces viable protoscolices, thereby lowering surgical risks when combined with resection.[175][176] For functional ovarian cysts, hormonal therapies such as combined oral contraceptives suppress ovulation and prevent recurrence, though they show limited efficacy in resolving existing cysts and are more effective prophylactically.[177]Indications for these approaches include persistent symptoms, suspicion of malignancy based on imaging or biomarkers, or evidence of recurrence following prior interventions. Complete surgical removal is prioritized when feasible, as it correlates with postoperative recurrence rates below 10%, particularly for hydatid and benign cystic lesions.[178]Robotic-assisted surgery has enhanced precision in cyst excision, especially for cysts in complex anatomical locations like the mediastinum or choledochal regions, by enabling three-dimensional visualization and tremor filtration; this has reduced intraoperative complications and blood loss compared to traditional laparoscopy.[179]
Associated Conditions
Polycystic Diseases
Polycystic diseases encompass a group of hereditary disorders characterized by the development of multiple cysts in various organs, primarily the kidneys and liver, due to genetic mutations affecting cellular signaling pathways. Autosomal dominant polycystic kidney disease (ADPKD) is the most common form, resulting from mutations in the PKD1 gene on chromosome 16 (accounting for approximately 78% of cases) or the PKD2 gene on chromosome 4 (about 15%), with the remainder attributed to other rare genes.[180] These mutationsencode polycystin-1 and polycystin-2, proteins localized to primary cilia in renal tubular epithelial cells, leading to a ciliopathy that disrupts mechanosensation of tubular fluid flow and promotes abnormal cell proliferation, fluid secretion, and cyst expansion.[181] ADPKD has a prevalence of about 1 in 1,000 individuals worldwide.[180] Cysts typically become detectable in the kidneys of affected individuals by age 30 in roughly 50% of cases, progressing to end-stage renal disease (ESRD) in approximately 50% by age 60.[182]A significant extrarenal manifestation of ADPKD is polycystic liver disease (PLD), which occurs either in isolation (autosomal dominant PLD, or ADPLD) or concurrently with ADPKD, affecting up to 80% of ADPKD patients by age 30.[183] Isolated PLD, caused by mutations in PRKCSH, SEC63, or other genes involved in protein processing, is rarer with a prevalence of around 1 in 100,000 and predominantly affects women (up to 80% of symptomatic cases), often leading to more numerous and larger cysts due to hormonal influences like estrogen.[184] In both forms, progressive cyst growth can result in massive hepatomegaly, compressing adjacent structures and causing symptoms such as abdominal distension, pain, or early satiety, though many cases remain asymptomatic until advanced stages.[185]Common complications of these polycystic diseases include hypertension, which develops in 50-70% of ADPKD patients early in the disease course due to renin-angiotensin system activation from cyst compression and vascular changes, and cyst hemorrhage, occurring in about 20-40% of cases and presenting as gross hematuria or flank pain. Management remains challenging, with no cure available; however, tolvaptan, a vasopressin V2 receptor antagonist that inhibits cyclic AMP-mediated cyst growth, was approved by the FDA in 2018 for slowing ADPKD progression in at-risk adults.[186] Clinical trials demonstrated that tolvaptan reduces the annual decline in estimated glomerular filtration rate by 26% compared to placebo over three years, highlighting a key advancement in addressing disease progression gaps, though its use is limited by potential hepatotoxicity and requires careful monitoring.[187] For severe PLD, options like somatostatin analogs may reduce cyst volume, but evidence is less robust than for renal-focused therapies. The KDIGO 2025 guideline offers comprehensive updated recommendations for ADPKD evaluation, management, and treatment.[188]
Cystic Fibrosis and Related Disorders
Cystic fibrosis (CF) is an autosomal recessive genetic disorder primarily affecting individuals of Caucasian descent, with an incidence of approximately 1 in 2,500 live births. It results from mutations in the CFTR gene, which encodes the cystic fibrosis transmembrane conductance regulator (CFTR) protein, a chlorideion channel essential for epithelial transport.[189] Over 2,000 CFTR mutations have been identified, with the most common being the ΔF508 deletion, accounting for about 70% of cases in Caucasian populations.[190]The core pathophysiology involves defective CFTR function, leading to impaired chloridesecretion and excessive sodium absorption across epithelial surfaces, which dehydrates airway surface liquid and produces thick, viscous mucus.[189] In the respiratory tract, this mucus obstructs airways, promotes bacterial colonization (e.g., by Pseudomonas aeruginosa), and triggers chronic inflammation and recurrent infections. Over time, these processes cause bronchiectasis, characterized by irreversible bronchial dilation that often appears cystic on imaging due to wall destruction and fibrosis, though these are not true epithelial-lined cysts but rather pseudocystic dilatations from ongoing damage.[189] Pancreatic involvement is common, with approximately 85% of CF patients developing exocrine pancreatic insufficiency early in life due to viscous secretions plugging ducts, leading to atrophy, fibrosis, and cystic dilation of pancreatic ducts.[191]Advancements in CFTR modulator therapies have significantly altered disease progression. The triple combination therapy elexacaftor/tezacaftor/ivacaftor (ETI), approved in 2019 for patients with at least one F508del mutation, corrects CFTR protein folding and function, resulting in a mean improvement in percent predicted forced expiratory volume in 1 second (ppFEV1) of 14% compared to controls in phase 3 trials.[192] Long-term data through 2023 indicate sustained benefits, including reduced pulmonary exacerbations and evidence of regression in bronchiectatic and cystic lung changes, alongside improvements in nutritional status that mitigate pancreatic complications. In December 2024, the FDA approved vanzacaftor/tezacaftor/deutivacaftor (Alyftrek), a next-generation triple modulator for eligible patients, further advancing CFTR-targeted therapies.[193]Related mucociliary clearance disorders share features of viscous secretions and cystic-like dilatations but differ in etiology. Primary ciliary dyskinesia (PCD), an autosomal recessive condition with an estimated incidence of 1 in 15,000 live births, arises from genetic defects in ciliary structure or motility, impairing mucus clearance and leading to chronic rhinosinusitis with potential cystic mucosal changes and bronchiectasis.[194] Shwachman-Diamond syndrome (SDS), caused by mutations in the SBDS gene, presents with exocrine pancreatic insufficiency in nearly all cases due to fatty replacement and ductal obstruction, alongside neutropenia and skeletal abnormalities.[195] These conditions highlight the spectrum of genetic mucociliary disorders that produce pseudocystic lesions distinct from neoplastic or infectious cysts.